### ANTARES PHARMA, INC.

Form 4

Common

Stock

09/28/2015

September 30, 2015

#### **OMB APPROVAL** UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB** 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or 0.5 response... Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Flynn James E Issuer Symbol ANTARES PHARMA, INC. [ATRS] (Check all applicable) (First) (Middle) (Last) 3. Date of Earliest Transaction (Month/Day/Year) Director \_X\_\_ 10% Owner \_X\_ Other (specify Officer (give title 780 THIRD AVENUE, 37TH 09/28/2015 below) below) FLOOR, Possible Member of 10% Group (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) Form filed by One Reporting Person X\_ Form filed by More than One Reporting NEW YORK, NY 10017 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (A) (Instr. 4) Transaction(s) or

								L.P. $(1)$ $(2)$
Common Stock	09/28/2015	S	226,857	D	\$ 1.8019	5,885,100	I	Through Deerfield Partners, L.P. (1) (2)
Common Stock	09/28/2015	S	469,224	D	\$ 1.8147	7,020,902	I	Through Deerfield International

Amount

288,726 D

(D)

Price

Code V

S

(Instr. 3 and 4)

7,490,126

I

Through Deerfield

International

Master Fund,

## Edgar Filing: ANTARES PHARMA, INC. - Form 4

								Master Fund, L.P. (1) (2)
Common Stock	09/28/2015	S	368,676	D	\$ 1.8147	5,516,424	I	Through Deerfield Partners, L.P.
Common Stock	09/29/2015	S	42,728	D	\$ 1.81	6,978,174	I	Through Deerfield International Master Fund, L.P. (1) (2)
Common Stock	09/29/2015	S	33,572	D	\$ 1.81	5,482,852	I	Through Deerfield Partners, L.P. (1) (2)
Common Stock	09/29/2015	S	23,700	D	\$ 1.81	3,365,146	I	Through Deerfield Special Situations Fund, L.P. (1) (2)
Common Stock	09/29/2015	S	19,976	D	\$ 1.8208	6,958,198	I	Through Deerfield International Master Fund, L.P. (1) (2)
Common Stock	09/29/2015	S	15,696	D	\$ 1.8208	5,467,156	I	Through Deerfield Partners, L.P. (1) (2)
Common Stock	09/29/2015	S	11,081	D	\$ 1.8208	3,354,065	I	Through Deerfield Special Situations Fund, L.P. (1) (2)
Common Stock	09/29/2015	S	43,845	D	\$ 1.83	6,914,353	I	Through Deerfield International Master Fund, L.P. (1) (2)
Common Stock	09/29/2015	S	34,450	D	\$ 1.83	5,432,706	I	Through Deerfield Partners, L.P. (1) (2)
	09/30/2015	S	59,248	D		3,294,817	I	

### Edgar Filing: ANTARES PHARMA, INC. - Form 4

Common Stock					\$ 1.6921			Through Deerfield Special Situations Fund, L.P. (1) (2)
Common Stock	09/30/2015	S	106,820	D	\$ 1.6921	6,807,533	I	Through Deerfield International Master Fund, L.P. (1) (2)
Common Stock	09/30/2015	S	83,930	D	\$ 1.6921	5,348,776	I	Through Deerfield Partners, L.P. (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

9. Nu Deriv Secu Bene Own Follo Repo Trans (Insti

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	e and	8. Price of	9
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration Da	ate	Amou	nt of	Derivative	J
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	,
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ities	(Instr. 5)	]
	Derivative				Securities			(Instr.	3 and 4)		(
	Security				Acquired						]
					(A) or						]
					Disposed						-
					of (D)						(
					(Instr. 3,						
					4, and 5)						
									Amount		
									or		
						Date	Expiration	Title	Number		
						Exercisable	Date	11110	of		
				Code V	(A) (D)				Shares		
				Code V	(II) $(D)$				Dilaics		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
<b>F-</b>	Director	10% Owner	Officer	Other			
Flynn James E							
780 THIRD AVENUE, 37TH FLOOR		X		Possible Member of 10% Group			
NEW YORK, NY 10017							

Reporting Owners 3

### Edgar Filing: ANTARES PHARMA, INC. - Form 4

Deerfield Mgmt L.P. 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
DEERFIELD MANAGEMENT CO 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
DEERFIELD PARTNERS, LP 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
Deerfield International Master Fund, L.P. 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
Deerfield Special Situations Fund, L.P. 780 3RD AVENUE 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group

# **Signatures**

/s/ Jonathan Isler 09/30/2015

\*\*Signature of
Reporting Person

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P., Deerfield Special
- (1) Situations Fund, L.P. and Deerfield International Master Fund, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

### **Remarks:**

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4